Anti-VEGF therapy for retinal vein occlusions

C Campa, G Alivernini, E Bolletta… - Current drug …, 2016 - ingentaconnect.com
Retinal vein occlusion (RVO) is the second most common cause of visual loss in the
Western World. RVO is usually classified into branch RVO (BRVO) and central RVO (CRVO) …

A sustained intravitreal drug delivery system with remote real time monitoring capability

H Hou, A Nieto, A Belghith, K Nan, Y Li, WR Freeman… - Acta biomaterialia, 2015 - Elsevier
Many chorioretinal diseases are chronic and need sustained drug delivery systems to keep
therapeutic drug level at the disease site. Many intravitreal drug delivery systems under …

Diameters and wall-to-lumen ratio of retinal arterioles in patients with retinal vein occlusion before and after treatment with dexamethasone intravitreal implants

F Semeraro, A Russo, D Rizzoni, P Danzi… - Journal of Ocular …, 2014 - liebertpub.com
Background: To evaluate the diameters and wall-to-lumen ratio (WLR) of retinal arterioles in
patients with retinal vein occlusion (RVO) before and after a 0.7 mg dexamethasone (DEX) …

Research progress of the diagnosis and treatment for retinal vein occlusion

W Bin, JIA Shu-Qin… - International Eye Science, 2014 - pesquisa.bvsalud.org
Retinal vein occlusion (RVO) is a common vascular disease of the retina and is one of the
main reasons for blindness. ln recent years, there have been some new understanding …

[PDF][PDF] Farmaci intravitreali nelle malattie retiniche: proprietà farmacologiche e aderenza alla terapia

AP Caputi, F Rossi - Soc. Ital. di Farmacol, 2015 - sif-website.s3.amazonaws.com
La terapia farmacologica per il trattamento delle malattie retiniche ha compiuto negli ultimi
anni notevoli passi avanti soprattutto grazie alla conoscenza dei meccanismi patogenetici di …

[引用][C] 视网膜静脉阻塞的诊断与治疗研究进展

王彬, 贾淑琴, 霍建新 - 国际眼科杂志, 2014